BACKGROUND/AIMS: Patients with choroidal melanoma can develop psychological morbidity because of visual disability, pain, facial deformity, and fears of metastatic disease. The aim of this study was to report on the prevalence of symptoms, moods, and well-being after radiotherapy or enucleation for choroidal melanoma and how these outcomes changed over time. METHODS: Participants were mailed questionnaires approximately 6 months following treatment, then annually on every anniversary of their treatment. RESULTS: Soon after enucleation, patients experienced visual difficulties because of loss of stereopsis and visual field and were concerned about their appearance and about metastatic disease. After radiotherapy, patients were more concerned about local tumor recurrence and more troubled by diplopia and headache. Over time, visual difficulties diminished after enucleation but increased in patients who had received radiotherapy, with concerns about metastasis, loss of health, and tumor recurrence diminishing in both groups. Anxiety tended to diminish whereas depression increased, especially after enucleation. Emotional well-being improved after both kinds of treatment, whereas functional and physical well-being diminished after enucleation but improved after radiotherapy. Self-reported quality of life diminished equally with both kinds of treatment. CONCLUSION: The findings of this study should help physicians understand what patients tend to feel after treatment for choroidal melanoma.
BACKGROUND/AIMS: Patients with choroidal melanoma can develop psychological morbidity because of visual disability, pain, facial deformity, and fears of metastatic disease. The aim of this study was to report on the prevalence of symptoms, moods, and well-being after radiotherapy or enucleation for choroidal melanoma and how these outcomes changed over time. METHODS: Participants were mailed questionnaires approximately 6 months following treatment, then annually on every anniversary of their treatment. RESULTS: Soon after enucleation, patients experienced visual difficulties because of loss of stereopsis and visual field and were concerned about their appearance and about metastatic disease. After radiotherapy, patients were more concerned about local tumor recurrence and more troubled by diplopia and headache. Over time, visual difficulties diminished after enucleation but increased in patients who had received radiotherapy, with concerns about metastasis, loss of health, and tumor recurrence diminishing in both groups. Anxiety tended to diminish whereas depression increased, especially after enucleation. Emotional well-being improved after both kinds of treatment, whereas functional and physical well-being diminished after enucleation but improved after radiotherapy. Self-reported quality of life diminished equally with both kinds of treatment. CONCLUSION: The findings of this study should help physicians understand what patients tend to feel after treatment for choroidal melanoma.
Authors: Timothy Pearman; Betina Yanez; John Peipert; Katy Wortman; Jennifer Beaumont; David Cella Journal: Cancer Date: 2014-05-22 Impact factor: 6.860
Authors: K J Cruickshanks; D G Fryback; D M Nondahl; N Robinson; U Keesey; D S Dalton; D M Robertson; S R Chandra; W F Mieler; Z N Zakov; P L Custer; L V Del Priore; D M Albert Journal: Arch Ophthalmol Date: 1999-04
Authors: Bertil Damato; Laura Hope-Stone; Bruce Cooper; Steve L Brown; Peter Salmon; Heinrich Heimann; Laura B Dunn Journal: Am J Ophthalmol Date: 2018-03-17 Impact factor: 5.258
Authors: Michele Melia; Claudia S Moy; Sandra M Reynolds; James A Hayman; Timothy G Murray; Kenneth R Hovland; John D Earle; Natalie Kurinij; Li Ming Dong; Päivi H Miskala; Connie Fountain; David Cella; Carol M Mangione Journal: Arch Ophthalmol Date: 2006-02
Authors: Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry Journal: Eye (Lond) Date: 2022-08-08 Impact factor: 4.456